Optimal Surgical Timing in KIT Exon 11-Mutant GIST: Insights from Radiographic and Pathology-Integrated Responses After Neoadjuvant Imatinib
Posted inGeneral Surgery news Oncology

Optimal Surgical Timing in KIT Exon 11-Mutant GIST: Insights from Radiographic and Pathology-Integrated Responses After Neoadjuvant Imatinib

This study compares radiographic versus pathology-integrated response metrics to identify optimal surgical timing after neoadjuvant imatinib treatment in KIT exon 11-mutant gastrointestinal stromal tumors (GIST). Pathology measures indicate a later window of near-maximal treatment effect than radiographic analysis.
Durable Efficacy and Safety of Avutometinib plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from a 2-Year ENGOT-OV60/GOG-3052/RAMP 201 Follow-up
Posted innews OB/GYN & Women’s Health Oncology

Durable Efficacy and Safety of Avutometinib plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from a 2-Year ENGOT-OV60/GOG-3052/RAMP 201 Follow-up

A 2-year follow-up of the ENGOT-OV60/GOG-3052/RAMP 201 trial confirms that the combination of avutometinib and defactinib offers sustained benefit and manageable safety in recurrent low-grade serous ovarian cancer, particularly in patients with KRAS mutations.
Precision Microbiome Therapeutics: Faecalibacterium prausnitzii EXL01 for Prevention of Multiple-Recurrent Clostridioides difficile Infection
Posted inClinical Updates news

Precision Microbiome Therapeutics: Faecalibacterium prausnitzii EXL01 for Prevention of Multiple-Recurrent Clostridioides difficile Infection

Faecalibacterium prausnitzii EXL01, a single commensal bacterial strain, shows promise in preventing multiple-recurrent CDI by restoring key microbiome functions, including bile acid metabolism and butyrate production, with safety and efficacy comparable to fecal microbiota transplantation.